Myriad Genetics (MYGN) vs Achieve Life Sciences (QUIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Achieve Life Sciences is the larger company by market cap ($573.2 million vs $523.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MYGN | QUIT |
|---|---|---|
| Share price | $5.46 | $5.56 |
| Market cap | $523.74M | $573.25M |
| 1-day change | -1.44% | -5.28% |
| YTD return | -11.22% | — |
| 1-year return | -26.02% | — |
| 5-year return | -79.48% | — |
| EPS (TTM) | $-1.35 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $824.50M | — |
| Revenue growth (YoY) | -1.56% | — |
| Net income (latest FY) | $-365.90M | $-54.65M |
| Gross margin | 69.93% | — |
| Operating margin | -46.96% | — |
| Net margin | -44.38% | — |
| 52-week high | $8.09 | $8.64 |
| 52-week low | $2.74 | $2.62 |
| Distance from 52-week high | -32.51% | -35.65% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +8.06% | +162.23% |
| Average volume | 2.26M | 1.38M |
| Shares outstanding | 95.92M | 103.10M |
| Employees | 2,700 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
About Achieve Life Sciences
QUIT stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
MYGN vs QUIT FAQ
Which is bigger, Myriad Genetics or Achieve Life Sciences?
Achieve Life Sciences (QUIT) is larger, with a market capitalization of $573.25M compared with $523.74M for Myriad Genetics (MYGN).
Are Myriad Genetics and Achieve Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.